Ken Griffin Halozyme Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 39,600 shares of HALO stock, worth $1.87 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

39,600

Previous 19,100 107.33%

Holding current value

$1.87 Million

Previous $1 Million 126.5%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$37.81 - $52.4 $1.75 Million - $2.43 Million	46,333 Added 15.37%	347,699 $18.2 Million
Q1 2024 May 15, 2024	BUY	$33.68 - $41.95 $3.93 Million - $4.89 Million	116,602 Added 63.11%	301,366 $12.3 Million
Q4 2023 Feb 14, 2024	BUY	$33.32 - $42.1 $8,463 - $10,693	254 Added 0.14%	184,764 $6.83 Million
Q3 2023 Nov 14, 2023	SELL	$36.46 - $44.03 $35.3 Million - $42.6 Million	-967,309 Reduced 83.98%	184,510 $7.05 Million
Q2 2023 Aug 14, 2023	BUY	$30.28 - $38.74 $6.98 Million - $8.93 Million	230,398 Added 25.0%	1,151,819 $41.5 Million
Q1 2023 May 15, 2023	BUY	$32.86 - $55.7 $22 Million - $37.3 Million	669,147 Added 265.25%	921,421 $35.2 Million
Q4 2022 Feb 14, 2023	BUY	$40.06 - $59.44 $9.31 Million - $13.8 Million	232,326 Added 1164.66%	252,274 $14.4 Million
Q3 2022 Nov 14, 2022	SELL	$38.53 - $51.78 $20.1 Million - $27 Million	-522,398 Reduced 96.32%	19,948 $789,000
Q2 2022 Aug 15, 2022	BUY	$37.35 - $48.3 $19.9 Million - $25.7 Million	532,478 Added 5396.01%	542,346 $23.9 Million
Q1 2022 May 16, 2022	SELL	$31.97 - $41.06 $4.4 Million - $5.65 Million	-137,702 Reduced 93.31%	9,868 $394,000
Q4 2021 Feb 14, 2022	BUY	$31.82 - $40.75 $2.56 Million - $3.28 Million	80,421 Added 119.77%	147,570 $5.93 Million
Q3 2021 Nov 15, 2021	SELL	$38.47 - $46.42 $1.43 Million - $1.73 Million	-37,252 Reduced 35.68%	67,149 $2.73 Million
Q2 2021 Aug 16, 2021	SELL	$38.84 - $51.31 $2.44 Million - $3.22 Million	-62,785 Reduced 37.55%	104,401 $4.74 Million
Q1 2021 May 17, 2021	BUY	$39.51 - $51.45 $180,126 - $234,560	4,559 Added 2.8%	167,186 $6.97 Million
Q4 2020 Feb 16, 2021	SELL	$25.81 - $43.62 $1.1 Million - $1.87 Million	-42,773 Reduced 20.82%	162,627 $6.95 Million
Q3 2020 Nov 16, 2020	SELL	$25.74 - $29.63 $2.17 Million - $2.5 Million	-84,316 Reduced 29.1%	205,400 $5.4 Million
Q2 2020 Aug 14, 2020	SELL	$16.25 - $26.81 $1.47 Million - $2.43 Million	-90,572 Reduced 23.82%	289,716 $7.77 Million
Q1 2020 May 15, 2020	BUY	$13.9 - $21.83 $1.37 Million - $2.16 Million	98,911 Added 35.15%	380,288 $6.84 Million
Q4 2019 Feb 14, 2020	BUY	$14.93 - $19.53 $125,994 - $164,813	8,439 Added 3.09%	281,377 $4.99 Million
Q3 2019 Nov 14, 2019	SELL	$15.2 - $17.69 $9.97 Million - $11.6 Million	-655,754 Reduced 70.61%	272,938 $4.23 Million
Q2 2019 Aug 14, 2019	BUY	$14.75 - $17.26 $4.58 Million - $5.36 Million	310,599 Added 50.25%	928,692 $16 Million
Q1 2019 May 15, 2019	BUY	$13.94 - $17.58 $5.14 Million - $6.48 Million	368,770 Added 147.91%	618,093 $0
Q4 2018 Feb 14, 2019	SELL	$13.33 - $18.66 $43,975 - $61,559	-3,299 Reduced 1.31%	249,323 $3.65 Million
Q3 2018 Nov 13, 2018	BUY	$16.68 - $18.41 $2.13 Million - $2.35 Million	127,877 Added 102.51%	252,622 $0
Q2 2018 Aug 10, 2018	BUY	$16.87 - $20.3 $1.19 Million - $1.43 Million	70,296 Added 129.1%	124,745 $0
Q1 2018 May 11, 2018	SELL	$17.06 - $21.2 $1.65 Million - $2.05 Million	-96,814 Reduced 64.0%	54,449 $1.07 Million
Q4 2017 Feb 09, 2018	BUY	$16.75 - $20.8 $2.1 Million - $2.61 Million	125,642 Added 490.39%	151,263 $3.07 Million
Q3 2017 Nov 09, 2017	BUY	$11.76 - $17.4 $301,302 - $445,805	25,621	25,621 $445,000

Others Institutions Holding HALO

# of Institutions

543

Shares Held

125M

Call Options Held

294K

Put Options Held

180K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.57B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account